Corporate Banner
Satellite Banner
Stem Cells, Cellular Therapy & Biobanking
>
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Cellular Dynamics Q4 Revenues Increase 41%

Published: Tuesday, March 11, 2014
Last Updated: Tuesday, March 11, 2014
Bookmark and Share
Cellular Dynamics International, Inc. reported financial results for the fourth quarter and for the fiscal year ended December 31, 2013.

“We continue to be pleased with the revenue growth of the company. Total revenues for the fiscal year ended December 31, 2013, increased 81% when compared to last year and average sales to our top 10 customers increased by 87% over the same period," said Bob Palay, Chairman and CEO of CDI.

“A growing number of pharmaceutical, biotech and CRO companies are adopting CDI’s products for their research programs. During the year ended December 31, 2013, CDI sold to 150 customers up from 128 for the year ended December 31, 2012. Our top 10 customers averaged $830,000 in revenue for the year ended December 31, 2013, up from $445,000 for the same period last year.  CDI achieved an important milestone when one of its customers, Eli Lilly and Company, generated over $2.0 million in revenue in a single year.  In addition, we also sold products to Nestle S.A. under our first supply agreement with a world leading food company.  We believe these results add to the growing evidence that our iCell® and MyCell® products are becoming an industry standard for manufactured human cells.

"Strategically, during the year CDI continued to make solid commercial progress in selling into both the in vitro market with our growing portfolio of iCell products and into the stem cell banking market.  During the fourth quarter we announced the $6.3 million contract with Coriell, which supplements our existing $16 million project with the California Institute for Regenerative Medicine (CIRM) to make iPS cell lines from 3,000 donors.  Our announced projects with the Jain Foundation and The Hamner Institutes for Health Sciences provide further evidence of the traction we're getting with our MyCell products within the stem cell banking market.  All of these projects take advantage of our proprietary episomal programming methodology, for which we received an issued patent during the fourth quarter of 2013."

Fourth Quarter 2013 Selected Financial Results
Revenue.
Total revenues for the fourth quarter of 2013 were $4.2 million compared to $2.9 million for the fourth quarter of 2012, an increase of 41%. Total revenues grew for three principal reasons: 1) increased unit sales of the Company’s iCell products, 2) significant increases in Collaborations, partnerships and other revenues arising from our center of excellence agreements with Eli Lilly and Company and AstraZeneca UK Limited, and 3) sales of new cell types in early release testing with our customers. Lastly, we also recognized our first revenues from our contract with CIRM.

Costs and expenses. Cost of product sales as a percentage of Product sales declined from 54% in the fourth quarter of 2012 to 27% in the fourth quarter of 2013.  As a consequence, gross margin from product sales remained attractive at 73% for the quarter.

Total costs and expenses (excluding Cost of product sales) were $9.8 million for the fourth quarter of 2013 compared to $7.5 million for the fourth quarter of 2012, an increase of 31%.  This growth is attributable principally to an increase in materials expense within our research and development organization, an increase in staffing within our sales and marketing organization and to general and administrative costs attributable to or triggered by our initial public offering.

Net loss. For the fourth quarter of 2013, Net loss was $6.7 million, or $0.43 per share, compared with a Net loss of $5.8 million, or $3.35 per share, for the fourth quarter of 2012.  Weighted average shares outstanding for the fourth quarter of 2013 was 15,756,363 versus 1,733,651 for the fourth quarter of 2012.  The difference in weighted average shares outstanding is principally attributable to both the common shares issued in our IPO and the conversion of our Series A and Series B preferred stock to common shares immediately prior to the consummation of our IPO. 

Fiscal Year 2013 Results
Revenue.
Total revenues for the year ended December 31, 2013, were $11.9 million compared to $6.6 million for the year ended December 31, 2012, an increase of 81%. Growth in Total revenues is primarily attributable to growth in unit sales of the Company’s iCell products and significant increases in Collaborations, partnerships and other revenues from our center of excellence agreements with Eli Lilly and Company and AstraZeneca UK Limited and sales of new cell types in early release testing with our customers.

Costs and expenses. Cost of product sales as a percentage of Product sales declined from 40% for the year 2012 to 29% for the year 2013.  Consequently, gross margin from product sales increased from 60% for the year 2012 to 71% for the year 2013.

Total costs and expenses (excluding Cost of product sales) were $33.8 million for the year 2013 compared to $26.7 million for the year 2012, an increase of 27%.  This growth is attributable principally to an increase in materials expense within our research and development organization, an increase in staffing within our sales and marketing organization and to general and administrative costs attributable to or triggered by our initial public offering.

Net loss. For the year 2013, Net loss was $25.0 million, or $3.17 per share, compared with a Net loss of $22.3 million, or $12.89 per share, for the year 2012.  Weighted average shares outstanding for the year 2013 was 7,878,060 versus 1,727,086 for 2012.  The difference in weighted average shares outstanding is principally attributable to both the common shares issued in our IPO and the conversion of our Series A and Series B preferred stock to common shares immediately prior to the consummation of our IPO. 

Cash and cash equivalents.  At December 31, 2013, Cash and cash equivalents totaled $62.0 million.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

SeouLin Bioscience to Distribute Cellular Dynamics' Products in Korea
SeouLin Bioscience will distribute CDI’s iCell® catalog of products.
Friday, August 21, 2015
Cellular Dynamics to Host Annual iForum™ Meetings
Meetings focused on human iPSC research and applications.
Friday, August 14, 2015
Cord Blood Registry and CDI Announce Collaboration
Collaboration to reprogram newborn stem cells into induced pluripotent stem cells.
Wednesday, January 14, 2015
Using iPSC-derived Cells to Coat Blood Vessels in Kidney Scaffolds
Cellular Dynamics and Northwestern University take first steps toward rebuilding an organ using manufactured human cells.
Tuesday, November 18, 2014
Cellular Dynamics International Reports Third Quarter 2014 Financial Results
Cellular Dynamics International, Inc. reported financial results for the third quarter and nine months ended September 30, 2014.
Tuesday, November 11, 2014
Cellular Dynamics Awarded $1.2 M NEI Contract
Contract will see company develop patient-derived stem cells in gear-up for age-related macular degeneration trial.
Tuesday, October 28, 2014
Cellular Dynamics Awarded NEI Contract
Contract awarded for the development of patient-derived stem cells in gear-up for age-related macular degeneration trial.
Monday, October 27, 2014
Cellular Dynamics Awarded U.S. Patent
Patent strengthens CDI’s position as leading manufacturer of human cells for research and clinical applications.
Friday, August 29, 2014
Cellular Dynamics Awarded Pluripotent Stem Cells Patents
Patents secure CDI’s position as leading manufacturer of human cells from most common, easily accessible donor source for research, drug discovery and regenerative medicine.
Thursday, July 10, 2014
Cellular Dynamics Signs Agreement with Nestlé Institute of Health Sciences
Agreement will see company to supply iCell® and MyCell® products for nutritional research.
Wednesday, January 08, 2014
The Hamner Institutes and Cellular Dynamics Collaborate
The parties will develop predictive in vitro screening assays for chemical, environmental and pharmaceutical toxicology assessments.
Monday, December 09, 2013
Jain Foundation Signs Agreement with Cellular Dynamics
Company will create iPSC lines from patients with muscular dystrophies for use as disease models for basic research and drug discovery.
Wednesday, December 04, 2013
CDI Reports Third Quarter 2013 Financial Results
Revenues more than double.
Wednesday, November 13, 2013
Cellular Dynamics Receives Formal Notice of Grant Award (NGA) for $16 Million Stem Cell Banking Project
NGA signifies entry into a definitive agreement and initiation of funding.
Tuesday, November 05, 2013
Cellular Dynamics Issued U.S. Patent
The patent relates to the method by which induced pluripotent stem cells are differentiated into the diverse types of endothelial and hematopoietic cells.
Thursday, October 17, 2013
Scientific News
The Mending Tissue - Cellular Instructions for Tissue Repair
NUS-led collaborative study identifies universal mechanism that explains how tissue shape regulates physiological processes such as wound healing and embryo development.
Tissue Bank Pays Dividends for Brain Cancer Research
Checking what’s in the bank – the Brisbane Breast Bank, that is – has paid dividends for UQ cancer researchers.
iPS Cells Discover Drug Target for Muscle Disease
Researchers have designed a model that reprograms fibroblasts to the early stages of their differentiation into intact muscle cells in a step towards a therapeutic for Duchenne muscular dystrophy.
Engineered Hot Fat Implants Reduce Weight Gain
Scientists at UC Berkeley have developed a novel way to engineer the growth and expansion of energy-burning “good” fat, and then found that this fat helped reduce weight gain and lower blood glucose levels in mice.
Transplanted Stem Cells Can Benefit Retinal Disease Sufferers
Tests on animal models show that MSCs secrete growth factors that suppress causes of diabetic retinopathy and macular degeneration.
MRI Scanners Can Steer Therapeutics to Specific Target Sites
Scientists from the University of Sheffield have discovered MRI scanners, normally used to produce images, can steer cell-based, tumour busting therapies to specific target sites in the body.
Team Finds Early Inflammatory Response Paralyzes T Cells
Findings could have enormous implications for immunotherapy, autoimmune disorders, transplants and other aspects of immunity.
Early Detection of Lung Cancer
The University of Manchester has signed a collaboration agreement with Abcodia to perform proteomics studies on a cohort of non-small cell lung cancer cases from the UKCTOCS biobank, with the aim of discovering new blood-based biomarkers for earlier detection of the disease.
Researchers Identify Drug Candidate for Skin, Hair Regeneration
Formerly undiscovered role of protein may lead to the development of new medications that stimulate hair and skin regeneration in trauma or burn victims.
Basis for New Treatment Options for a Fatal Leukemia in Children Revealed
Detailed molecular analyses allow new insights into the function of tumour cells and options for new treatments.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!